CY1120283T1 - Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης - Google Patents

Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης

Info

Publication number
CY1120283T1
CY1120283T1 CY20181100570T CY181100570T CY1120283T1 CY 1120283 T1 CY1120283 T1 CY 1120283T1 CY 20181100570 T CY20181100570 T CY 20181100570T CY 181100570 T CY181100570 T CY 181100570T CY 1120283 T1 CY1120283 T1 CY 1120283T1
Authority
CY
Cyprus
Prior art keywords
therapeutic system
interderative
rivastigmin
producers
administration
Prior art date
Application number
CY20181100570T
Other languages
Greek (el)
English (en)
Inventor
Heike Prinz
Björn Schurad
Thomas Beckert
Kristina Linder
Original Assignee
Luye Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120283(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Luye Pharma Ag filed Critical Luye Pharma Ag
Publication of CY1120283T1 publication Critical patent/CY1120283T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
    • A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
CY20181100570T 2009-12-22 2018-05-25 Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης CY1120283T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09180413 2009-12-22
EP10154648 2010-02-25
EP10790565.5A EP2515886B1 (de) 2009-12-22 2010-12-14 Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
PCT/EP2010/069654 WO2011076621A2 (de) 2009-12-22 2010-12-14 Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten

Publications (1)

Publication Number Publication Date
CY1120283T1 true CY1120283T1 (el) 2019-07-10

Family

ID=43383419

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100570T CY1120283T1 (el) 2009-12-22 2018-05-25 Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης

Country Status (16)

Country Link
US (1) US8962014B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2515886B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6083734B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101674240B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102711744B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010335309B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012017168B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2785117C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1120283T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2515886T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2670227T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX350357B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2515886T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2515886T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2515886T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011076621A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
WO2011053251A1 (en) 2009-10-30 2011-05-05 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
HUE027916T2 (en) * 2010-12-14 2016-11-28 Acino Ag Transdermal therapeutic system for administration of an active ingredient
EP2711002A4 (en) * 2011-05-20 2014-10-29 Sk Chemicals Co Ltd PLASTER WITH RIVASTIGMIN
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
CN103796645B (zh) 2011-08-31 2017-06-20 东洋油墨Sc控股株式会社 贴剂
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
CA2865715C (en) 2012-02-28 2018-06-19 Nichiban Co., Ltd. Transdermal patch
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
CN103933018A (zh) * 2013-01-18 2014-07-23 江苏康倍得药业有限公司 一种透皮给药系统
WO2015174502A1 (ja) 2014-05-15 2015-11-19 ニチバン株式会社 リバスチグミンを含有する貼付剤のための包装体
WO2016049035A1 (en) 2014-09-23 2016-03-31 Equistar Chemicals, Lp Polyolefin-based compositions, adhesives, and related multi-layered structures prepared therefrom
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
DE102015119789A1 (de) * 2015-11-16 2017-05-18 Denso-Holding Gmbh & Co. Korrosionsschutzzusammensetzung umfassend Polyisobutylene
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
TW201840307A (zh) 2017-03-24 2018-11-16 美商伊英克加利福尼亞有限責任公司 用於遞送活性分子的微胞系統
KR102366628B1 (ko) 2017-03-24 2022-02-22 이 잉크 캘리포니아 엘엘씨 활성제들의 투여 속도를 조절하기 위해 하전 또는 자성 입자들을 포함하는 마이크로셀 전달 시스템
CN111295182A (zh) 2017-11-14 2020-06-16 伊英克加利福尼亚有限责任公司 包括多孔导电电极层的电泳活性物质递送系统
US12121616B2 (en) * 2018-04-17 2024-10-22 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of solifenacin
WO2019232077A1 (en) 2018-05-29 2019-12-05 Chrono Therapeutics Inc. Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
US11938214B2 (en) 2019-11-27 2024-03-26 E Ink Corporation Benefit agent delivery system comprising microcells having an electrically eroding sealing layer
EP4236926A4 (en) 2020-10-29 2024-08-28 E Ink Corporation MICROCELL SYSTEMS FOR DELIVERY OF BENEFICIAL AGENTS
WO2022093547A1 (en) 2020-10-29 2022-05-05 E Ink California, Llc Microcell systems for delivering hydrophilic active molecules

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
JPS63307818A (ja) 1987-06-08 1988-12-15 Sekisui Chem Co Ltd 経皮吸収貼付剤
JPH07116025B2 (ja) 1988-03-11 1995-12-13 積水化学工業株式会社 貼付剤
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
JPH08193030A (ja) 1995-01-12 1996-07-30 Nitto Denko Corp エメダスチン貼付製剤
JPH10152434A (ja) * 1996-09-26 1998-06-09 Nitto Denko Corp 経皮吸収型製剤
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
DE10141652B4 (de) 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
WO2003032960A1 (fr) * 2001-10-17 2003-04-24 Hisamitsu Pharmaceutical Co., Inc. Preparations pour absorption percutanee
JP4478757B2 (ja) * 2002-04-19 2010-06-09 日東電工株式会社 ビソプロロール含有貼付剤
BRPI0518396A2 (pt) * 2004-12-27 2008-11-18 Eisai R&D Man Co Ltd mÉtodo para estabilizaÇço de droga anti-demÊncia
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN1994290B (zh) * 2006-01-04 2011-03-16 上海医药工业研究院 卡巴拉汀透皮贴剂及其制备方法
MY149152A (en) 2006-05-08 2013-07-15 Teikoku Seiyaku Kk Percutaneous absorption preparations of antimentia drugs
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
JP2009022730A (ja) * 2007-06-18 2009-02-05 Kyoritsu Yakuhin Kogyo Kk 貼付剤

Also Published As

Publication number Publication date
EP2515886A2 (de) 2012-10-31
NO2515886T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-09-08
PT2515886T (pt) 2018-05-23
WO2011076621A2 (de) 2011-06-30
US20130261571A1 (en) 2013-10-03
KR101674240B1 (ko) 2016-11-08
JP6083734B2 (ja) 2017-02-22
US8962014B2 (en) 2015-02-24
BR112012017168B1 (pt) 2022-03-15
CA2785117A1 (en) 2011-06-30
BR112012017168A2 (pt) 2018-05-02
AU2010335309B2 (en) 2015-08-20
AU2010335309A1 (en) 2012-07-19
ES2670227T3 (es) 2018-05-29
PL2515886T3 (pl) 2018-08-31
MX350357B (es) 2017-09-05
MX2012007214A (es) 2012-09-12
CA2785117C (en) 2016-12-06
CN102711744B (zh) 2014-06-25
KR20120128606A (ko) 2012-11-27
JP2013515025A (ja) 2013-05-02
DK2515886T3 (en) 2018-06-14
EP2515886B1 (de) 2018-04-11
WO2011076621A3 (de) 2012-02-09
CN102711744A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
CY1120283T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης
CY1123712T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
CY1122812T1 (el) Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
CY1117770T1 (el) Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
CL2012000949A1 (es) Compuestos derivados de 3-[(4-fenilpiperidin-1-il)carbonill]piperidina inhibidores de la proteina hdm2; composicion farmaceutica que comprende unoi de los compustos; y su uso de los compuestos en la preparacion de un medicamento util para el tratamiento d distintos tipos de cancer, tales como vejiga, de colon de riñon y otros.
CR20150360A (es) Sistema de liberación transdérmica
SG184244A1 (en) Medical devices including medicaments and methods of making and using same
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
EA201190300A1 (ru) Микроэлектрод и множественные микроэлектроды, содержащие устройства для высвобождения лекарственных средств в ткани
CL2007002358A1 (es) Sistema de liberacion farmaceutica controlado, oral que comprende uno o mas modificadores de ph, una capa aislante; procedimiento de preparacion; y su uso para el tratamiento de trastornos del sistema nervioso central, sistema afectivo, del sueno y s
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
MX376862B (es) Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
CL2009001556A1 (es) Sistema de administración transdermica de fármacos que comprende una capa que contiene fármaco que comprende una matriz polimérica que contiene estradiol como unico fármaco; método de elaboración; útil para administrar estradiol.
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
WO2009120484A3 (en) Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
AR100353A1 (es) Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
CY1113575T1 (el) Χρηση συνθεσεων οπιοειδων σε συσκευες χορηγησης δραστικης ουσιας χωρις βελονα
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.